Race Oncology Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAONF research report →
About the company
Based in Sydney, Australia, Race Oncology Limited is an Australian precision oncology firm that commenced operations in 2011. The company's primary focus is the development of Zantrene, a potent small molecule designed to inhibit the fatso/fat mass and obesity associated protein (FTO). This therapeutic agent is currently in Phase II/III clinical trials, exploring its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer.
- CEO
- Daniel Tillett
- IPO
- 2021
- HQ
- Sydney, NSW, AU
Price Chart
- Market Cap
- $451.73M
- P/E
- -42.33
- P/S
- 569.49
- P/B
- 17.09
- EV/EBITDA
- -41.64
- Div Yield
- 0.00%
- Gross Margin
- 49.76%
- Op Margin
- -1294.94%
- Net Margin
- -1190.78%
- ROE
- -47.44%
- ROIC
- -33.36%
- Revenue
- $6.04M · 50.96%
- Net Income
- $-4,787,258 · 65.36%
- EPS
- $-0.03 · 66.90%
- Op Income
- $-3,771,834
- FCF YoY
- 52.08%
- 52W High
- $2.60
- 52W Low
- $0.83
- 50D MA
- $1.22
- 200D MA
- $1.22
- Beta
- 1.91
- Avg Volume
- 1
Get TickerSpark's AI analysis on RAONF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RAONF coverage
Recent articles, reports, and earnings notes.
No research on RAONF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAONF report →Similar companies
Peers in the same neighborhood.